Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.49 USD
+0.05 (2.05%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.48 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CRBU 2.49 +0.05(2.05%)
Will CRBU be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRBU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRBU
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade
Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?
Other News for CRBU
Strategic Focus and Financial Runway Extension Bolster Caribou Biosciences’ Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Ufp Technologies (UFPT)
Evaluating Caribou Biosciences: Insights From 4 Financial Analysts
Caribou cuts 12% of workforce, extends cash runway into 2H 2026
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board